In Europe, azacitidine is the only hypomethylating agent approved for the treatment of patients with int-2-/high-risk myelodysplastic syndromes, offering significantly improved survival compared with conventional care. However, not all patients treated with azacitidine respond to treatment, and the vast majority of responders subsequently relapse. Currently, no standard care regimens have been established for patients after failure of azacitidine. Here, we discuss treatment options after loss of response or progression on azacitidine. In addition, we briefly consider optimization of first-line treatment along with potential biomarkers for identifying and monitoring response during treatment with azacitidine.

Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations / Santini, Valeria; Prebet, Thomas; Fenaux, Pierre; Gattermann, Norbert; Nilsson, Lars; Pfeilstöcker, Michael; Vyas, Paresh; List, Alan F.. - In: LEUKEMIA RESEARCH. - ISSN 0145-2126. - ELETTRONICO. - 38:(2014), pp. 1381-1391. [10.1016/j.leukres.2014.09.008]

Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations

SANTINI, VALERIA;
2014

Abstract

In Europe, azacitidine is the only hypomethylating agent approved for the treatment of patients with int-2-/high-risk myelodysplastic syndromes, offering significantly improved survival compared with conventional care. However, not all patients treated with azacitidine respond to treatment, and the vast majority of responders subsequently relapse. Currently, no standard care regimens have been established for patients after failure of azacitidine. Here, we discuss treatment options after loss of response or progression on azacitidine. In addition, we briefly consider optimization of first-line treatment along with potential biomarkers for identifying and monitoring response during treatment with azacitidine.
2014
38
1381
1391
Goal 3: Good health and well-being for people
Santini, Valeria; Prebet, Thomas; Fenaux, Pierre; Gattermann, Norbert; Nilsson, Lars; Pfeilstöcker, Michael; Vyas, Paresh; List, Alan F.
File in questo prodotto:
File Dimensione Formato  
LEUKRES-prebet.pdf

Accesso chiuso

Tipologia: Pdf editoriale (Version of record)
Licenza: Tutti i diritti riservati
Dimensione 501.75 kB
Formato Adobe PDF
501.75 kB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1078042
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 29
  • ???jsp.display-item.citation.isi??? 22
social impact